(1-Methyl-3-phenyl-propylamino)-3,4-dihydroxy-acetophenon

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1-Methyl-3-phenyl-propylamino)-3,4-dihydroxy-acetophenon
• 英文别名: 1-(3,4-dihydroxy-phenyl)-2-(1-methyl-3-phenyl-propylamino)-ethanone；1-(3,4-Dihydroxy-phenyl)-2-(1-methyl-3-phenyl-propylamino)-aethanon；1-(3,4-Dihydroxyphenyl)-2-(4-phenylbutan-2-ylamino)ethanone
• 化学式: C₁₈H₂₁NO₃
• 分子量: 299.37
• InChiKey: GEJJIDMFPAQQOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 作用下， 生成 (1-Methyl-3-phenyl-propylamino)-3,4-dihydroxy-acetophenon
  参考文献：
  名称：

  Moed et al., Recueil des Travaux Chimiques des Pays-Bas, 1955, vol. 74, p. 919,922

  摘要：

  DOI：

文献信息

• Anti-glycation agents for preventing age- diabetes- and smoking-related complications
  申请人：Yeboah Faustinus

  公开号：US20050043408A1

  公开（公告）日：2005-02-24

  The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

  这项发明提供了新的蛋白质糖基化抑制剂，通过高通量筛选检测从化合物库中鉴定出来。所鉴定的抗糖基化剂具有多种化学结构，可用于预防或治疗与年龄、糖尿病和吸烟有关的并发症，包括神经病变、肾病、眼部病理或胶原组织的机械性能丧失。在被鉴定为具有抗糖基化活性的化合物中，特别感兴趣的是肾上腺素及其类似物，特别是D-肾上腺素及其类似物，可用于预防或治疗与年龄、糖尿病和吸烟有关的眼部病理。
• ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS
  申请人：YEBOAH Faustinus

  公开号：US20080139664A1

  公开（公告）日：2008-06-12

  The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

  该发明提供了新的蛋白质糖基化抑制剂，通过高通量筛选检测从化合物库中确定。所确定的抗糖基化剂具有各种化学结构，并可用于预防或治疗与年龄、糖尿病和吸烟相关的并发症，包括神经病变、肾病、眼部病理或胶原组织机械性能的丧失。在被确定为具有抗糖基化活性的化合物中，特别感兴趣的是肾上腺素及其类似物，特别是D-肾上腺素及其类似物，这些物质特别适用于预防或治疗与年龄、糖尿病和吸烟相关的眼部病理。
• ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES
  申请人：Konishi Yasuo

  公开号：US20110060045A1

  公开（公告）日：2011-03-10

  The invention disclosed relates to the use of anti-glycation agents of formula (I), wherein X represents NR 7 , wherein R 7 represents hydrogen atom or an acyl group derived from a linear, branched or cyclic C 1-10 aliphatic acid or a C 6-10 aromatic acid, R 1 represents hydrogen atom, NH 2 , or a linear, branched or cyclic C 1-10 alkyl which may be substituted with a C 6-10 aromatic group, R 2 represents hydrogen atom, a linear, branched or cyclic C 1-10 alkyl, or COOH group, R′ 2 represents hydrogen atom or a linear, branched or cyclic C 1-10 alkyl group, R 3 represents hydrogen atom, ═O, OR 8 , SR 8 , or NR 8 R 9 , wherein R 8 and R 9 represent hydrogen atom, a linear, branched or cyclic C 1-10 alkyl, or an acyl group derived from a linear or branched C 1-10 aliphatic acid or a C 6-10 aromatic acid, provided that R 8 and R 9 are not both an acyl group, R 4 and R 5 each independently represents OH, NH 2 , or SH, R 6 represents hydrogen, F, Cl, Br, I, OR 10 , or SR 10 , wherein R 10 represents hydrogen or an acyl group derived from a linear or branched C 1-10 aliphatic acid or a C 6-10 aromatic acid, R 6 may be present more than once and each R 6 may be the same or different, a physiologically tolerated salt, prodrug, physiologically functional derivative or mixture thereof, such as (S)-isoproterenol, and its prodrug, (S)-isoproterenol dipivalate hydrochloride on the initiation of diabetic cataracts. (S)-Isoproterenol is a strong anti-glycation agent with an in vitro IC 50 value of 16.8±0.8 μM. (S)-isoproterenol dipivalate hydrochloride was prepared in eye drop form at 0.1% concentration and was applied to diabetic rats twice a day up to 30 weeks. No cataract was observed in non-diabetic rats with or without treatment of the prodrug. In diabetic rats without treatment of the prodrug (group III), 88% of eyes got cataract at 8.6±1.5 weeks. In diabetic rats with treatment of the prodrug, only 53% of the eyes initiated cataract at 8.6±1.2 weeks, and the remaining 26% of the eyes prolonged the initiation to 17.1±3.1 weeks. Furthermore, no cataract was observed in 21% of the eyes even at 30 weeks.
• [EN] ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS<br/>[FR] AGENTS ANTI-GLYCATION DESTINES A LA PREVENTION DES COMPLICATIONS LIEES A L'AGE, AU DIABETE ET AU TABAGISME
  申请人：CA NAT RESEARCH COUNCIL

  公开号：WO2003032969A2

  公开（公告）日：2003-04-24

  The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.